Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hagendoorn, J.
Right arrow Articles by Jain, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hagendoorn, J.
Right arrow Articles by Jain, R. K.
[Cancer Research 66, 3360-3364, April 1, 2006]
© 2006 American Association for Cancer Research

Priority Reports

Onset of Abnormal Blood and Lymphatic Vessel Function and Interstitial Hypertension in Early Stages of Carcinogenesis

Jeroen Hagendoorn1, Ricky Tong1, Dai Fukumura1, Qingcong Lin2, Jennifer Lobo1, Timothy P. Padera1, Lei Xu1, Raju Kucherlapati2 and Rakesh K. Jain2

1 Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School and 2 Harvard Medical School-Partners Healthcare Center for Genetics and Genomics, Boston, Massachusetts

Requests for reprints: Rakesh K. Jain, Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Cox 7, Boston, MA 02114. Phone: 617-726-4083; Fax: 617-724-1819; E-mail: jain{at}steele.mgh.harvard.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Recent improvements in diagnostic methods have opened avenues for detection and treatment of (pre)malignant lesions at early stages. However, due to the lack of spontaneous tumor models that both mimic human carcinogenesis and allow direct optical imaging of the vasculature, little is known about the function of blood and lymphatic vessels during the early stages of cancer development. Here, we used a spontaneous carcinogenesis model in the skin of DNA polymerase {eta}–deficient mice and found that interstitial fluid pressure was already elevated in the hyperplastic/dysplastic stage. This was accompanied by angiogenic blood vasculature that exhibited altered permeability, vessel compression, and decreased {alpha}-smooth muscle actin–positive perivascular cell coverage. In addition, the lymphatic vessels in hyperplastic/dysplastic lesions were partly compressed and nonfunctional. These novel insights may aid early detection and treatment strategies for cancer. (Cancer Res 2006; 66(7): 3360-4)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Although it is well established that angiogenesis precedes neoplastic transformation (1, 2), it is unclear how the newly formed blood vessels function and affect the local tissue microenvironment. Moreover, the status of lymphatic vessels during early stages of carcinogenesis is unknown (3). Because optimal scheduling of antiangiogenic agents can increase the effectiveness of conventional cytotoxic therapy by reversing abnormalities in tumor blood vasculature (4), understanding the functional changes in blood and lymphatic vasculature may have broad implications for treatment of early cancer stages.

Tumor blood and lymphatic vessels are structurally and functionally abnormal. This abnormality can result from an imbalance in molecular factors regulating vessel growth and maturation as well as from compressive mechanical forces generated by proliferating neoplastic cells (5, 6). Abnormal growth and maturation can lead to hyperpermeable, tortuous blood vessels whereas compressive forces can cause vessel lumen collapse and thus restrict flow. Although changes in vascular structure during the transition from hyperplasia/dysplasia to neoplasia have been investigated in several murine spontaneous tumor models (7, 8), to date, corresponding changes in blood and lymphatic vessel function and the interstitial fluid pressure have not been reported. We have recently developed mice genetically deficient for DNA polymerase {eta} (pol {eta}) that exhibit a reproducible pattern of skin squamous carcinomas induced by UVB irradiation (described in ref. 9). Here, we use pol {eta}–/– mice to measure interstitial fluid pressure and the structural and functional status of blood and lymphatic vessels in the early stages of carcinogenesis.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals and UVB irradiation. Mice made deficient in pol {eta} by targeted deletion of exon 4 of the pol {eta} gene were used in these experiments (9). These mice exhibit a well-defined and reproducible pattern of UVB light–induced carcinogenesis similar to human xeroderma pigmentosum variant (shown in detail in Figs. 4 and 5A of ref. 9). Pol {eta}–/– and wild-type (WT) mice were UVB irradiated thrice a week at a dose of 3.75 kJ/m2 each time with a bank of two UVB lamps. UVB flux was measured by a UVX-31 digital radiometer (Blak-Ray lamp Model XX-15M and Model UVX-31, UV Products, Inc., Upland, CA). For all the experiments, Pol {eta}–/– mice were used that had received ~10 weeks of irradiation (and had developed hyperplastic/dysplastic lesions) or at least 5 months of irradiation (tumor stage) and compared with WT control mice that had received 3 or 5 months of irradiation.

Interstitial fluid pressure measurements. Interstitial fluid pressure was measured using the wick-in-needle technique (10). One or two interstitial fluid pressure measurements were obtained per ear in WT mice (n = 5) and in pol {eta}–/– mice during the hyperplastic/dysplastic stage (n = 8) and the tumor stage (n = 6). Briefly, 26-gauge needles with a 1-mm side hole 2 mm from the tip were filled with two surgical sutures (6-0 ethilon). The needle was connected to a pressure transducer by polyethylene tubing filled with sterile heparinized saline. The pressure transducer was connected to an amplifier and the signal was sent to a chart recorder. For all measurements, good fluid communication was confirmed by compressing and decompressing the tubing with a screw clamp and verifying a proper response. The mean pressure was taken before and after compression-decompression.

Blood and lymphatic vessel function. To assess vascular function intravitally, angiography and lymphangiography were done in WT, hyperplastic/dysplastic, and tumor-bearing animals (n = 3-5 per group per experiment). Angiography was done using i.v. injection of FITC-dextran (Mr 2,000,000; Sigma, St. Louis, MO; ref. 6). Lymphangiography was done after slow, intradermal injection of 1 to 2 µL of FITC-dextran (Mr 2,000,000; Sigma) in the peripheral ear or the surface of tumors. The vessels were imaged by single-photon fluorescence microscopy as previously described (11).

Vascular permeability measurements. The effective microvascular permeability coefficient was measured as described (12) using tetramethyl-rhodamine–labeled or cyanine-5-labeled bovine serum albumin.

Immunohistochemistry and image analysis. For immunohistochemistry, WT, hyperplastic/dysplastic, and tumor-bearing animals (n = 3-5 per group) were injected i.v. with biotinylated Lycopersicon esculentum lectin (10 µg/g body weight; Vector Laboratories, Inc., Burlingame, CA). After 5 minutes, animals were sacrificed by percardiac perfusion with 4% paraformaldehyde. Five-micron-thick paraffin sections were prepared from excised, fixed ears. Lectin was detected by horseradish peroxidase–conjugated streptavidin (Vector Elite ABC kit, Vector Laboratories). Immunohistochemistry was done for MECA32 (1:200; BD Biosciences, San Jose, CA), {alpha}-smooth muscle actin ({alpha}SMA; 1:1,000; Sigma), and LYVE-1 (1:2,000; Upstate, Charlottesville, VA) using microwave antigen retrieval (DakoCytomation, Glostrup, Denmark) and Envision Plus Kit (DakoCytomation). To quantify blood and lymphatic vessel morphology and pericyte coverage, digital images were taken from immunohistochemistry sections. Vessels (lectin/MECA32 or LYVE-1 positive structures) were hand-traced using ImageJ image analysis software as described (6) to calculate the perimeter and aspect ratio—the ratio of maximum to minimum diameter—of stained vessels. Perivascular cell coverage was quantified by double staining of perfused lectin and {alpha}SMA. Total number of vessels and vessels covered by pericytes were counted in all groups.

Gene array and quantitative PCR. To determine expression of genes involved in angiogenesis, total RNA was extracted from WT and hyperplastic/dysplastic pol {eta}–/– ears (n = 2-3 per group) using TRIzol reagent (Invitrogen, Carlsbad, CA). To screen for relative expression of multiple genes, cDNA arrays containing 96 genes involved in angiogenesis were used according to the instructions of the manufacturer (GEArray Q Series). Chemilluminescent spots were quantified by densitometry and normalized with ß-actin (FluoroChem 8800 system). A change of >3-fold in pol {eta}–/– versus WT ears was considered significant differential expression. The mRNA levels of several molecules associated with angiogenesis [Ang1, Ang2, EDG1, IFN{gamma}, SPHK1, Tie1, transforming growth factor (TGF)-{alpha}, TGF-ß receptor 3, vascular cell adhesion molecule, vascular endothelial growth factor (VEGF), VEGF receptor 1, VEGF receptor 2, platelet-derived growth factor (PDGF)-B, PDGF-C, PDGF-D, and PDGFR-ß] were further determined using real-time quantitative PCR. Quantitative real-time PCRs were done on the ABI 7700 sequence detection system (Applied Biosystems, Foster City, CA). All experiments were done in duplicate and relative quantification done by comparing to ß-actin. A serial dilution of template was used to verify primer efficiency. Primer sequences can be found in Supplementary Fig. S1.

Statistics. Results are presented as mean ± SE. Student t test was used to evaluate statistical significance (defined as P < 0.05). F test was used to calculate equality of variances. All experiments were done under the guidelines of the Massachusetts General Hospital Animal Care and Use Committee.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Elevated interstitial fluid pressure in hyperplastic/dysplastic lesions and tumors. We measured interstitial fluid pressure in the ears of WT and pol {eta}–/– mice in the hyperplastic/dysplastic stage or with established tumors. In the hyperplastic/dysplastic stage, interstitial fluid pressure was increased compared with WT mice (4.5 ± 0.8 versus –0.2 ± 0.7 mm Hg, respectively; P < 0.05). In tumors, interstitial fluid pressure was even further increased (9.7 ± 1.1 mm Hg; P < 0.05; Fig. 1A ). Thus, these data show that interstitial fluid pressure is already increased in the hyperplastic/dysplastic stage of carcinogenesis.


Figure 1
View larger version (67K):
[in this window]
[in a new window]
  		Figure 1. Abnormal tumor microenvironment and blood vasculature during carcinogenesis. A, interstitial fluid pressure (IFP) was elevated in hyperplastic/dysplastic lesions and tumors. Intravital microscopy of the ears of WT (B) and pol {eta}–/– mice (C) in the hyperplastic/dysplastic stage was done after i.v. injection of FITC-dextran. Blood vessels in hyperplastic/dysplastic lesions became structurally abnormal and hyperpermeable. The blood vessels have multiple leaky spots, which were reflected in the permeability measurement. Bar, 200 µm. Low magnification (D-F; bar, 100 µm) and high magnification (G-I; bar, 20 µm) of perfused lectin (brown) and {alpha}SMA (red) double staining of WT (D and G) and pol {eta}–/– mice in the hyperplastic/dysplastic stage (E and H) and in the established tumor stage (F and I). Whereas blood vessels in WT ears are mostly opened and covered by {alpha}SMA-positive cells, vessels in hyperplastic/dysplastic lesions and tumor vessels lack perivascular cells (H and I, arrows). The vessels also appear compressed. J, quantification of the aspect ratio—the ratio of maximum to minimum axes—of perfused vessels show that vessels in hyperplastic/dysplastic lesions are partially compressed (5.43 ± 0.38; n = 164) whereas tumor vessels are compressed to a greater extent (7.59 ± 0.55; n = 142) when compared with WT vessels (3.87 ± 0.50; n = 41). An aspect ratio of 1 represents a perfect circle. The larger the aspect ratio, the greater the amount of vessel compression. K, quantification of perivascular cell coverage shows that WT vessels are completely covered by perivascular cells whereas hyperplastic/dysplastic vessels and tumor vessels have incomplete perivascular cell coverage. A vessel is considered covered when at least 25% of the perimeter is covered by {alpha}SMA-positive cells.

 
Abnormal vasculature in hyperplastic/dysplastic lesions and tumors. Elevated interstitial fluid pressure can result from abnormal blood vessels as well as lymphatic vessels. Thus, we first did intravital microscopy to analyze vascular function. Angiography revealed that hyperplastic/dysplastic lesions in pol {eta}–/– mice had abnormal, dilated vessels with multiple leaky spots (Fig. 1B and C). The microvascular permeability in hyperplastic/dysplastic lesions displayed a wide variability compared with WT ears (9.37 x 10–7 ± 7.52 x 10–7 versus 1.20 x 10–7 ± 4.22 x 10–8 cm/s, respectively; P < 0.0005, F test), showing that part of the vessels in hyperplastic/dysplastic regions had an increased permeability. Immunohistochemistry also revealed that vascular density was significantly increased in hyperplastic/dysplastic ears of pol {eta}–/– mice (Fig. 1D and E). Blood vessels in hyperplastic/dysplastic lesions were compressed compared with WT ears, but less compressed than in fully established tumors (Fig. 1D-F and J). In addition, {alpha}SMA-positive perivascular cell coverage was decreased in hyperplastic/dysplastic lesions and even further decreased in tumors (Fig. 1G-I and K). Taken together, these data show that angiogenic vasculature becomes chaotic, hyperpermeable, and functionally abnormal in the hyperplastic/dysplastic stage of carcinogenesis.

Abnormal lymphatics in hyperplastic/dysplastic lesions and tumors. We next assessed whether structural and functional abnormalities of the lymphatics occurred in hyperplastic/dysplastic lesions. Lymphangiography in WT mice showed normal lymphatic networks (Fig. 2A ). In contrast, pol {eta}–/– ears in the hyperplastic/dysplastic stage showed irregular lymphatic networks that were locally compressed or dilated (Fig. 2B) whereas pol {eta}–/– tumors contained no functional lymphatics (data not shown). Immunohistochemistry confirmed that WT ears had circular, open lymphatic vessels (Fig. 2C). Lymphatic vessels in hyperplastic/dysplastic lesions were more compressed compared with WT controls (Figs. 2D and 3A ) and only 82% of vessels had an open lumen versus 100% in controls (Fig. 3B). Perilesional lymphatics, on the other hand, were dilated as shown by their increased perimeter (128.9 ± 6.9 versus 89.2 ± 2.1 µm; P < 0.05; Figs. 2D and 3C). Tumor lymphatics had a decreased perimeter compared with lymphatics in premalignant lesions (78.3 ± 3.2 versus 90.1 ± 3.1 µm; P < 0.05), were even more compressed, and only 10% had an open lumen (Figs. 2E and 3A-C).


Figure 2
View larger version (80K):
[in this window]
[in a new window]
  		Figure 2. Abnormal lymphatics during carcinogenesis. A, in WT mice, intravital fluorescence lymphangiography revealed a normal drainage pattern from the tip of the ear in the proximal direction (arrow, direction of flow). Bar, 200 µm. B, in pol {eta}–/– mice in the hyperplastic/dysplastic stage, an irregular network of functional lymphatics with localized compression and dilation (arrowheads) was observed (arrow, direction of flow). Bar, 200 µm. C, LYVE-1 staining of the ears of WT mice in axial cross sections revealed circular, open lymphatics (black arrows) on both sides of the ear cartilage. Bar, 100 µm. D, consistent with lymphangiography, ears in the hyperplastic/dysplastic stage in pol {eta}–/– mice showed narrowed lymphatics (red arrows) in areas of (epi)dermal hyperplasia (asterisks) whereas dilated vessels (black arrow) were observed in adjacent areas. Bar, 100 µm. E, the lymphatics in advanced tumors have no open lumen. Bar, 100 µm.

 

Figure 3
View larger version (19K):
[in this window]
[in a new window]
  		Figure 3. Lymphatic size and compression during carcinogenesis. A, quantification of the aspect ratio of stained vessels showed that lymphatics in hyperplastic/dysplastic lesions were more compressed than in WT controls (4.8 ± 0.2 versus 3.5 ± 0.1; P < 0.05). Intratumor lymphatics were even more compressed (7.5 ± 0.4 versus 3.5 ± 0.1; P < 0.05). An aspect ratio of 1 represents a perfect circle. The larger the aspect ratio, the greater the amount of vessel compression. B, quantification of the fraction of open vessels showed that in WT controls, 100% of vessels had an open lumen versus 82% of vessels in hyperplastic/dysplastic lesions and 10% of intratumor vessels. C, quantification of mean lymphatic perimeter showed that lymphatics around hyperplastic/dysplastic lesions were increased in size compared with WT animals. Intratumor lymphatics had a decreased size compared with WT animals. A to C, Peri-H/D, lymphatics located in the margin of or within ~150 µm from hyperplastic/dysplastic regions; H/D, lymphatics located in hyperplastic/dysplastic regions; Tumor, lymphatics in established tumors. D, quantitative reverse transcription-PCR analysis of the ears of pol {eta}–/– mice in the hyperplastic/dysplastic stage (KO) and WT mice. Ratios of relative gene expression (KO/WT) normalized to ß-actin are depicted. *, P < 0.05, compared with a ratio of 1 (null hypothesis).

 
Gene array analysis of hyperplastic/dysplastic lesions. To determine if molecules that have a role in blood and lymphatic vessel formation and remodeling were induced or blocked, we did gene array analysis for 96 genes associated with angiogenesis (Table 1 ). Gene array densitometry and subsequent quantitative PCR showed no different expression of major determinants of blood and lymphatic vessel formation and remodeling in the hyperplastic/dysplastic pol {eta}–/– ears versus WT, except for a 3.9-fold up-regulation of IFN{gamma} as confirmed by quantitative PCR (Fig. 3D). Possibly, accumulation or activation of immune cells in hyperplastic/dysplastic lesions contributed to this up-regulation of IFN{gamma} (13).


View this table:
[in this window]
[in a new window]
  		Table 1. Angiogenic gene array analysis of the ears of pol {eta}–/– mice in the hyperplastic/dysplastic stage and WT mice

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Although the importance of angiogenesis during early neoplastic transformation is well recognized, there are no reports that assess the function of blood and lymphatic vasculature during the early stages of cancer development, presumably due to a lack of suitable animal models. In contrast to other transgenic mice (14), pol {eta}–/– mice exhibit UV light–induced multistep carcinogenesis in the ears that can be easily accessed with intravital microscopy. Using this novel approach, we found that blood vessels begin to show abnormalities such as increased vascular density, dilation, and hyperpermeability. Blood vessels are also collapsed and have incomplete perivascular cell coverage in the hyperplastic/dysplastic stage. Gene array analysis did not detect different expression of major determinants of blood and lymphatic vessel formation and remodeling in the hyperplastic/dysplastic stage, except for up-regulation of IFN{gamma}. These findings are consistent with earlier work that showed no different expression of well-known angiogenic molecules in the hyperplasia stage (7). IFN{gamma} can be expressed by lymphocytes involved in an immune reaction against tumor cells and stroma (15). At the same time, lymphocytes may play a role in early tumor progression by expression of matrix metalloproteinase 9 (16). Further investigation will need to address the recruitment and role of lymphocytes and other immune cells in early stages of cancer.

In concert with our previous findings (6, 11, 17), we found no functional lymphatics in established pol {eta}–/– tumors. Surprisingly, even in the hyperplastic/dysplastic stage, lesional lymphatics were more compressed than normal vessels and a significant fraction had no open lumen. At the same time, perilesional vessels were increased in size, possibly providing partially compensatory drainage of the excess interstitial fluid (3). Nearly all lymphatic structures inside tumors were compressed and their size was decreased, suggesting that these are remnants of lymphatic vessels. Thus, lymphatic vessel compression with resultant functional abnormalities in lymph drainage already occurs during early stages of carcinogenesis.

Both abnormal, hyperpermeable blood vasculature and impaired lymphatic function lead to increased interstitial fluid pressure, a major transport barrier for the delivery of therapeutic agents in tumors (18). The earliest increase in interstitial fluid pressure reported before the current study was within days of implanting cancer cells in the dorsal skinfold chamber (19). Using our spontaneous tumor model, we observed increased interstitial fluid pressure in the hyperplastic/dysplastic stage. Therefore, similar to tumors, delivery of chemopreventive agents to hyperplastic/dysplastic lesions may be hindered by elevated interstitial fluid pressure. Moreover, these findings suggest that optimal scheduling of antiangiogenic agents to normalize the tumor vasculature and enhance the efficacy of chemoradiation therapy, as shown in previous studies (20–22), may also be useful to treat early stages of cancer. Furthermore, elevated interstitial fluid pressure could be used to detect early stages of cancer when the disease is more amenable to treatment (19). Thus, these novel insights may be useful in early cancer detection and treatment.


   Acknowledgments
 
Grant support: NIH grants CA-84301 and EH-11040 (R. Kucherlapati), CA-80124 and CA-85140 (R.K. Jain), and CA-96915 (D. Fukumura).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Sylvie Roberge, Carolyn Smith, and Melanie Fortier for excellent technical assistance; Drs. Yves Boucher and Satoshi Kashiwagi for helpful suggestions; and Tara Belezos for assistance.


   Footnotes
 
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

J. Hagendoorn, R. Tong, and D. Fukumura contributed equally to this work.

Received 7/27/05. Revised 1/13/06. Accepted 2/ 2/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst 1978;61:639–43.[Medline]
  2. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61.[CrossRef][Medline]
  3. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst 2002;94:417–21.[Free Full Text]
  4. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58–62.[Abstract/Free Full Text]
  5. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685–93.[CrossRef][Medline]
  6. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumour vessels. Nature 2004;427:695.[CrossRef][Medline]
  7. Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int J Dev Biol 1998;42:995–1002.[Medline]
  8. Herzig M, Christofori G. Recent advances in cancer research: mouse models of tumorigenesis. Biochim Biophys Acta 2002;1602:97–113.[Medline]
  9. Lin Q, Clark AB, McCulloch SD, et al. Increased susceptibility to ultraviolet-induced skin carcinogenesis in Pol {eta}-deficient mice. Cancer Res 2006;66:87–94.[Abstract/Free Full Text]
  10. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991;51:6691–4.[Abstract/Free Full Text]
  11. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883–6.[Abstract/Free Full Text]
  12. Yuan F, Leunig M, Berk DA, Jain RK. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc Res 1993;45:269–89.[CrossRef][Medline]
  13. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860–7.[CrossRef][Medline]
  14. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 2002;108:135–44.[CrossRef][Medline]
  15. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005;17:180–6.[CrossRef][Medline]
  16. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481–90.[CrossRef][Medline]
  17. Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res 2004;64:4400–4.[Abstract/Free Full Text]
  18. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655–7.[CrossRef][Medline]
  19. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996;56:4264–6.[Abstract/Free Full Text]
  20. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731–6.[Abstract/Free Full Text]
  21. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145–7.[CrossRef][Medline]
  22. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24–40.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. C. Spalding, R. Watson, M. E. Davis, A. C. Kim, T. S. Lawrence, and E. Ben-Josef
Inhibition of Protein Kinase C{beta} by Enzastaurin Enhances Radiation Cytotoxicity in Pancreatic Cancer
Clin. Cancer Res., November 15, 2007; 13(22): 6827 - 6833.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Hayashi, P. Jiang, K. Yamauchi, N. Yamamoto, H. Tsuchiya, K. Tomita, A.R. Moossa, M. Bouvet, and R. M. Hoffman
Real-time Imaging of Tumor-Cell Shedding and Trafficking in Lymphatic Channels
Cancer Res., September 1, 2007; 67(17): 8223 - 8228.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. V. Dickson, J. B. Hamner, T. L. Sims, C. H. Fraga, C. Y.C. Ng, S. Rajasekeran, N. L. Hagedorn, M. B. McCarville, C. F. Stewart, and A. M. Davidoff
Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy
Clin. Cancer Res., July 1, 2007; 13(13): 3942 - 3950.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Eichten, W. C. Hyun, and L. M. Coussens
Distinctive Features of Angiogenesis and Lymphangiogenesis Determine Their Functionality during De novo Tumor Development
Cancer Res., June 1, 2007; 67(11): 5211 - 5220.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. I. Harrell, B. M. Iritani, and A. Ruddell
Tumor-Induced Sentinel Lymph Node Lymphangiogenesis and Increased Lymph Flow Precede Melanoma Metastasis
Am. J. Pathol., February 1, 2007; 170(2): 774 - 786.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. A. Dumstorf, A. B. Clark, Q. Lin, G. E. Kissling, T. Yuan, R. Kucherlapati, W. G. McGregor, and T. A. Kunkel
Participation of mouse DNA polymerase {iota} in strand-biased mutagenic bypass of UV photoproducts and suppression of skin cancer
PNAS, November 28, 2006; 103(48): 18083 - 18088.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hagendoorn, J.
Right arrow Articles by Jain, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hagendoorn, J.
Right arrow Articles by Jain, R. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online